24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial

@inproceedings{Soininen201724monthIW,
  title={24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial},
  author={Hilkka Soininen and Alina Solomon and Pieter Jelle Visser and Suzanne B. Hendrix and K Blennow and Miia Kivipelto and Tobias Hartmann and Ilona Hallikainen and Merja Hallikainen and Seppo Helisalmi and Tarja Lappalainen and Yawu Liu and Teemu Paajanen and Lars-Olof Wahlund and Yvonne Freund-Levi and Niels Andreasen and G{\"o}ran Hagman and Stina Lindblom and Klaus Fassbender and Matthias Riemenschneider and Marcus O W Grimm and Aline Klees-Rollmann and Maxine Luley and Epameinondas Lyros and Robert Schomburg and Jennifer Kennel and Daniela Ramelli and Lutz Fr{\"o}lich and Lucrezia Hausner and Christoph Laske and Thomas Leyhe and Christian Mychajliw and Niklas Koehler and Stephan Schiekofer and Hans Hermann Kl{\"u}nemann and Johannes Schr{\"o}der and Dieter L{\"u}tjohann and Philip Scheltens and Ineke A van Rossum and Nienke M.E. Scheltens and Daniela Bertens and Mara Ten Kate and Frederik Barkhof and Johanna ML Henselmans and Gerwin Roks and Anneke M. J. van Hees and Noel Ellison},
  booktitle={The Lancet Neurology},
  year={2017}
}
BACKGROUND Nutrition is an important modifiable risk factor in Alzheimer's disease. Previous trials of the multinutrient Fortasyn Connect showed benefits in mild Alzheimer's disease dementia. LipiDiDiet investigated the effects of Fortasyn Connect on cognition and related measures in prodromal Alzheimer's disease. Here, we report the 24-month results of the trial. METHODS LipiDiDiet was a 24-month randomised, controlled, double-blind, parallel-group, multicentre trial (11 sites in Finland… CONTINUE READING
3 Citations
22 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Developing Drugs for the Treatment of Early Stage Disease, Draft guidance

  • U. S. Department of Health, Human Services Food, Drug Administration Center for Drug Evaluation, Research . Guidance for Industry, Alzheimer’s Disease
  • 2013. http://www.fda.gov/downloads/Drugs…
  • 2016
1 Excerpt

Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial

  • EP Moll van Charante, E Richard, LS Eurelings
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…